NovaBridge Biosciences (NBP) Receivables (2018 - 2023)

NovaBridge Biosciences (NBP) has 6 years of Receivables data on file, last reported at $2.7 million in Q4 2023.

• Receivables for Q4 2023 came in at $2.7 million, down 42.66% year-over-year; the trailing twelve-month figure through Dec 2023 was $2.7 million (down 42.66% YoY), and the FY2023 annual result was $2.7 million, up 198.62% from the prior year.
• Receivables declined to $2.7 million in Q4 2023 per NBP's latest filing, from $4.7 million in the prior quarter.
• Over five years, Receivables peaked at $44.2 million in Q2 2022 and troughed at $202589.4 in Q3 2019.
• A 5-year average of $13.7 million and a median of $3.8 million in 2019 frame the typical range for Receivables.
• On a YoY basis, Receivables climbed as much as 3390.62% in 2021 and fell as far as 82.3% in 2021.
• A 5-year view of Receivables shows it stood at $2.9 million in 2019, then jumped by 1163.44% to $36.1 million in 2020, then plunged by 82.3% to $6.4 million in 2021, then retreated by 25.78% to $4.7 million in 2022, then tumbled by 42.66% to $2.7 million in 2023.
• Business Quant data shows NBP's Receivables at $2.7 million in Q4 2023, $4.7 million in Q4 2022, and $44.2 million in Q2 2022.